Literature DB >> 394890

In vivo anti-nuclear antibodies in epithelial biopsies in SLE and other connective tissue diseases.

J V Wells, J Webb, M Van Deventer, B Fry, K M Pollard, J Raftos, W Monk, D S Nelson.   

Abstract

In vivo anti-nuclear antibody (ANA) was observed by direct immunofluorescence microscopy in epithelial cell nuclei in forty-four biopsies from thirty-three patients. The tissue containing the ANA was macroscopically normal in twenty-seven patients. The thirty-three patients with in vivo biopsy ANA included twenty-three with SLE, three with mixed connective tissue disease, two each with multi-system Sjögren's syndrome, dermatomyositis, and progressive systemic sclerosis, and one with rheumatoid arthritis. Features of sicca syndrome were noted in seventeen patients. The patterns of the in vivo biopsy ANA in the thirty-three patients were speckled (21), homogeneous (6), nodular (2), and both speckled and homogeneous (4). Complement was not detected in the epithelial cell nuclei. Immunoglobulin(s) and/or complement were deposited along the dermoepidermal junction in thirty-two of the forty-four biopsies, and in dermal blood vessels in twenty-two biopsies. Each patient had serum ANA against rat liver substrate; twenty-seven had high titre ANA (1 in 1000 or greater). Elevated levels of DNA-binding were found in twenty patients (61%), but the level of DNA-binding did not correlate with the intensity of in vitro biopsy ANA staining. Serum antibody to ribonucleoprotein (RNP) was present in eight of the twenty-three patients tested (35%), all eight patients having clinical features of sicca syndrome. Hypocomplementaemia was found in thirteen patients (40%), all of whom had active SLE. In vivo biopsy ANA appears to be a real phenomenon of unknown aetiology, and not an artifact, which is found in some patients with active multisystem autoimmune disease, especially SLE.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 394890      PMCID: PMC1537926     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Myasthenia gravis, systemic lupus erythematosus and urticaria. (Case 1). Myasthenia gravis and herpetiform acantholysis. (Case 2).

Authors:  C R Darley; D D Munro; P F Borrie
Journal:  Proc R Soc Med       Date:  1977-10

2.  Observations on the in vivo reaction of antinuclear antibodies with epidermal cells.

Authors:  G T Izuno
Journal:  Br J Dermatol       Date:  1978-04       Impact factor: 9.302

3.  Nuclear deposits of immunoglobulins in skin of patients with systemic lupus erythematosus.

Authors:  S Shu; T Provost; M B Croxdale; M Reichlin; E H Beutner
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

4.  Mixed connective tissue disease in childhood. A clinical and serologic survey.

Authors:  B H Singsen; B H Bernstein; H K Kornreich; K K King; V Hanson; E M Tan
Journal:  J Pediatr       Date:  1977-06       Impact factor: 4.406

5.  Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors.

Authors:  D Alarcon-Segovia; A Ruiz-Arguelles; E Fishbein
Journal:  Nature       Date:  1978-01-05       Impact factor: 49.962

6.  Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.

Authors:  G C Sharp; W S Irvin; C M May; H R Holman; F C McDuffie; E V Hess; F R Schmid
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

7.  Antinuclear antibody with distinct specificity for polymyositis.

Authors:  J F Wolfe; E Adelstein; G C Sharp
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

8.  Prospective analysis of antiribonucleoprotein antibodies in systemic lupus erythematosus.

Authors:  B Bresnihan; R Grigor; G R Hughes
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

9.  Epidermal nucleolar IgG deposition in clinically normal skin: clinical and serologic features of eight patients.

Authors:  S D Prystowsky; J N Gilliam; D L Tuffanelli
Journal:  Arch Dermatol       Date:  1978-04

10.  Acute pulmonary complications in systemic lupus erythematosus. Immunofluorescence and light microscopic study.

Authors:  L P Pertschuk; L F Moccia; Y Rosen; H Lyons; C M Marino; A A Rashford; C M Wollschlager
Journal:  Am J Clin Pathol       Date:  1977-11       Impact factor: 2.493

View more
  7 in total

1.  Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies.

Authors:  M H Foster; T Kieber-Emmons; M Ohliger; M P Madaio
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 2.  B cells and autoantibodies in the pathogenesis of lupus nephritis.

Authors:  M P Madaio
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

3.  In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies.

Authors:  P J Velthuis; L Kater; I van der Tweel; F G Meyling; R H Derksen; R J Hené; J A van Geutselaar; H Baart de la Faille
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

4.  Antibodies to histones in systemic lupus erythematosus: prevalence, specificity, and relationship to clinical and laboratory features.

Authors:  M G Cohen; K M Pollard; J Webb
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

5.  Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases.

Authors:  M G Cohen; J Webb
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

6.  Inhibition of adenovirus DNA synthesis in vitro by sera from patients with systemic lupus erythematosus.

Authors:  M S Horwitz; B R Friefeld; H D Keiser
Journal:  Mol Cell Biol       Date:  1982-12       Impact factor: 4.272

7.  Clinicopathological Significance among Patients with In vivo Epidermal Nuclear Staining by Direct Immunofluorescence Study.

Authors:  Wararat Sirikudta; Papapit Tuchinda; Leena Chularojanamontri; Kanokvalai Kulthanan; Samruay Pinkaew
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.